These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 16139439)

  • 1. Antiandrogen-like actions of an antioxidant on survivin, Bcl-2 and PSA in human prostate cancer cells.
    Gunawardena K; Campbell LD; Meikle AW
    Cancer Detect Prev; 2005; 29(4):389-95. PubMed ID: 16139439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with vitamins C plus E inhibits survivin and human prostate cancer cell growth.
    Gunawardena K; Campbell LD; Meikle AW
    Prostate; 2004 May; 59(3):319-27. PubMed ID: 15042608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone is a potential augmentor of antioxidant-induced apoptosis in human prostate cancer cells.
    Gunawardena K; Murray DK; Meikle AW
    Cancer Detect Prev; 2002; 26(2):105-13. PubMed ID: 12102144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear factor-kappaB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas.
    Angileri FF; Aguennouz M; Conti A; La Torre D; Cardali S; Crupi R; Tomasello C; Germanò A; Vita G; Tomasello F
    Cancer; 2008 May; 112(10):2258-66. PubMed ID: 18327814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
    Zhang M; Latham DE; Delaney MA; Chakravarti A
    Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.
    Liu CM; Lo YC; Tai MH; Wu BN; Wu WJ; Chou YH; Chai CY; Huang CH; Chen IJ
    Prostate; 2009 May; 69(6):610-23. PubMed ID: 19143029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curcumin blocks the activation of androgen and interlukin-6 on prostate-specific antigen expression in human prostatic carcinoma cells.
    Tsui KH; Feng TH; Lin CM; Chang PL; Juang HH
    J Androl; 2008; 29(6):661-8. PubMed ID: 18676361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells.
    Church DR; Lee E; Thompson TA; Basu HS; Ripple MO; Ariazi EA; Wilding G
    Prostate; 2005 May; 63(2):155-68. PubMed ID: 15486991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells.
    Gupta S; Afaq F; Mukhtar H
    Oncogene; 2002 May; 21(23):3727-38. PubMed ID: 12032841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
    Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
    Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
    Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
    Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer.
    Jiang C; Lee HJ; Li GX; Guo J; Malewicz B; Zhao Y; Lee EO; Lee HJ; Lee JH; Kim MS; Kim SH; Lu J
    Cancer Res; 2006 Jan; 66(1):453-63. PubMed ID: 16397261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells.
    Mori A; Lehmann S; O'Kelly J; Kumagai T; Desmond JC; Pervan M; McBride WH; Kizaki M; Koeffler HP
    Cancer Res; 2006 Mar; 66(6):3222-9. PubMed ID: 16540674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells.
    Lim JT; Piazza GA; Pamukcu R; Thompson WJ; Weinstein IB
    Clin Cancer Res; 2003 Oct; 9(13):4972-82. PubMed ID: 14581372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
    Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
    Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
    Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
    BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
    Jackson KM; Frazier MC; Harris WB
    Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
    Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
    Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
    Hellsten R; Johansson M; Dahlman A; Dizeyi N; Sterner O; Bjartell A
    Prostate; 2008 Feb; 68(3):269-80. PubMed ID: 18163422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
    Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
    Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.